Newer antidepressants and panic disorder: A meta-analysis

International Clinical Psychopharmacology

Volumn 28, Issue 1, 2013, Pages 33-45

  Andrisano, Costanza ^a   Chiesa, Alberto ^a,b   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

antidepressants; mirtazapine; panic disorder; reboxetine; selective serotonin reuptake inhibitors; venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; PAROXETINE; PLACEBO; REBOXETINE; SERTRALINE; VENLAFAXINE;

ANXIETY; ARTICLE; COCHRANE LIBRARY; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PANIC; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SYMPTOM; TREATMENT OUTCOME;

ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PANIC DISORDER; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871608801     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32835a5d2e     Document Type: Article

References (95)

1. American Psychiatric Association (2009). Treatment of patients with panic disorder. 2nd ed. Washington, DC: American Psychiatric Association; Available at: http://www. psychiatryonline. com/pracGuide/pracGuideTopic-9. aspx [Accessed 25 March 2012].
2. Amore M, Magnani K, Cerisoli M, Casagrande C, Ferrari G (1999). Panic disorder. A long-term treatment study: fluoxetine vs imipramine. Hum Psychopharmacol 14:429-434. (Pubitemid 29423676)
3. Bakker A, van Balkom AJ, Spinhoven P (2002). SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand 106:163-167.
4. Bakker A, van Balkom AJ, Stein DJ (2005). Evidence-based pharmacotherapy of panic disorder. Int J Neuropsychopharmacol 8:473-482. (Pubitemid 41002501)
5. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567-596. (Pubitemid 41578819)
6. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP (1998). Doubleblind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 155:36-42. (Pubitemid 28037546)
7. Bandelow B, Ruther E (2004). Treatment-resistant panic disorder. CNS Spectr 9:725-739.
8. Bandelow B, Sievert K, Rothemeyer M, Hajak G, Ruther E (1995). What treatments do patients with panic disorder and agoraphobia get? Eur Arch Psychiatry Clin Neurosci 245:165-171.
9. Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Goebel C, et al. (2004). Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry 65:405-413.
10. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Zohar J, et al. (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry 9:248-312.
11. Batelaan NM, Van Balkom AJ, Stein DJ (2011). Evidence-based pharmacotherapy of panic disorder: an update. Int J Neuropsychopharmacol1-13.
12. Bertani A, Perna G, Migliarese G, Di Pasquale D, Cucchi M, Caldirola D, et al. (2004). Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry 37:206-210. (Pubitemid 39286922)
13. Black DW, Wesner R, Bowers W, Gabel J (1993). A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 50:44-50. (Pubitemid 23026988)
14. Boshuisen ML, Slaap BR, Vester-Blokland ED, den Boer JA (2001). The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int Clin Psychopharmacol 16:363-368. (Pubitemid 33030053)
15. Brunello N, Racagni G (1998). Rationale for the development of noradrenaline reuptake inhibitors. Hum Psychopharmacol 13:13-19.
16. Carli V, Sarchiapone M, Camardese G, Romano L, DeRisio S (2002). Mirtazapine in the treatment of panic disorder. Arch Gen Psychiatry 59:661-662.
17. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746-758.
18. Cohen J (1992). A power primer. Psychol Bull 112:155-159.
19. Colditz GA, Miller JN, Mosteller F (1989). How study design affects outcomes in comparisons of therapy. I: medical. Stat Med 8:441-454. (Pubitemid 19105892)
20. Coplan JD, Papp LA, Martinez J, Pine D, Rosenblum LA, Cooper T, et al. (1995). Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. Am J Psychiatry 152: 619-622.
21. Dannon PN, Iancu I, Grunhaus L (2002). The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum Psychopharmacol 17:329-333. (Pubitemid 35189814)
22. Den Boer JA, Westenberg HG (1988). Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3:59-74.
23. Den Boer JA, Westenberg HG (1990). Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 102:85-94. (Pubitemid 20227533)
24. Durrleman S, Chaikin P (2003). The use of putative placebo in active control trials: two applications in a regulatory setting. Stat Med 22:941-952. (Pubitemid 36322096)
25. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634. (Pubitemid 27387172)
26. Ferguson JM, Khan A, Mangano R, Entsuah R, Tzanis E (2007). Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry 68:58-68. (Pubitemid 46220125)
27. Freire RC, Hallak JE, Crippa JA, Nardi AE (2011). New treatment options for panic disorder: clinical trials from 2000 to 2010. Expert Opin Pharmacother 12:1419-1428.
28. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N (2006). Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 59:7-10. (Pubitemid 41797469)
29. Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D (2001). Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 58:681-686. (Pubitemid 32651693)
30. Gorman J, Wolkow R (1994). Sertraline as a treatment for panic disorder. Neuropsychopharmacology 10:117-175.
31. Gulsun M, Doruk A, Uzun O, Turkbay T, Ozsahin A (2007). Effect of dissociative experiences on drug treatment of panic disorder. Clin Drug Investig 27: 583-590. (Pubitemid 47124100)
32. Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH (2004). The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 10:23-44. (Pubitemid 38381173)
33. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
34. Hedges LV, Olkin I (1985). Statistical methods for meta-analysis. Orlando, FL: Academic Press. Hoehn-Saric R, McLeod DR, Hipsley PA (1993). Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 13:321-326.
35. Humble M, Wistedt B (1992). Serotonin, panic disorder and agoraphobia: shortterm and long-term efficacy of citalopram in panic disorders. Int Clin Psychopharmacol 6 (Suppl 5):21-39.
36. Hunter JE, Schmidt FL (1990). Methods of meta-analysis. Correcting error and bias in research finding. Beverly Hills, CA: Sage Publications.
37. Jadad AR, Moore RA, Carroll D (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 17: 1-12. (Pubitemid 26120810)
38. Kamijima K, Kuboki T, Kumano H, Burt T, Cohen G, Arano I, et al. (2005). A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan. Int Clin Psychopharmacol 20:265-273. (Pubitemid 41192147)
39. Kim EJ, Yu BH (2005). Increased cholesterol levels after paroxetine treatment in patients with panic disorder. J Clin Psychopharmacol 25:597-599.
40. Kindler S, Dolberg OT, Cohen H, Hirschmann S, Kotler M (1997). The treatment of comorbid premature ejaculation and panic disorder with fluoxetine. Clin Neuropharmacol 20:466-471. (Pubitemid 27424338)
41. Lepola U, Leinonen E, Turtonen J, Pentinen J (1994). The effect of citalopram in panic disorder and agoraphobia. Nord J Psychiatry13-17.
42. Liebowitz MR, Asnis G, Mangano R, Tzanis E (2009). A double-blind, placebocontrolled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. J Clin Psychiatry 70: 550-561.
43. Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, et al. (1998). Sertraline in the treatment of panic disorder. A multi-site, doubleblind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 173: 54-60. (Pubitemid 28312204)
44. Lopez-Leon S, Janssens AC, Gonzalez-Zuloeta Ladd AM, Del-Favero J, Claes SJ, Oostra BA, et al. (2008). Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry 13:772-785. (Pubitemid 352032108)
45. Maron E, Shlik J (2006). Serotonin function in panic disorder: important, but why? Neuropsychopharmacology 31:1-11. (Pubitemid 43250937)
46. Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, et al. (1998). Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 155:1570-1577. (Pubitemid 28512027)
47. Michelson D, Allgulander C, Dantendorfer K, Knezevic A, Maierhofer D, Micev V, et al. (2001). Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry 179:514-518. (Pubitemid 34031676)
48. Mitte K (2005). A meta-analysis of the efficacy of psycho-and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 88:27-45. (Pubitemid 41160411)
49. Mochcovitch MD, Nardi AE (2010). Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies. Expert Rev Neurother 10:1285-1293.
50. Montanes-Rada F, de Lucas-Taracena MT, Sanchez-Romero S (2005). Mirtazapine versus paroxetine in panic disorder: an open study. Int J Psych Clin Pract 9:87-93. (Pubitemid 40874102)
51. Mullen B (1989). Advanced BASIC meta-analysis. In: Hillsdale NE, editor. Advanced BASIC meta-analysis. Hillsdale, NJ: Erlbaum.
52. Nair NP, Bakish D, Saxena B, Amin M, Schwartz G, West TE (1996). Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety 2:192-198. (Pubitemid 126812828)
53. Nardi AE, Valenca AM, Freire RC, Mochcovitch MD, Amrein R, Sardinha A, et al. (2011). Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. Braz J Med Biol Res 44:366-373.
54. Neuger J, Wistedt B, Sinner B, Aberg-Wistedt A, Stain-Malmgren R (2000). The effect of citalopram treatment on platelet serotonin function in panic disorders. Int Clin Psychopharmacol 15:83-91. (Pubitemid 30142800)
55. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, et al. (1995). Paroxetine in the treatment of panic disorder. A randomised, doubleblind, placebo-controlled study. Br J Psychiatry 167:374-379. (Pubitemid 26197752)
56. Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH (2001). An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 158:1989-1992. (Pubitemid 33104103)
57. Owens MJ, Nemeroff CB (1994). Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40:288-295. (Pubitemid 24072594)
58. Owens MJ, Krulewicz S, Simon JS, Sheehan DV, Thase ME, Carpenter DJ, et al. (2008). Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology 33:3201-3212.
59. Papp LA, Sinha SS, Martinez JM, Coplan JD, Amchin J, Gorman JM (1998). Lowdose venlafaxine treatment in panic disorder. Psychopharmacol Bull 34: 207-209. (Pubitemid 28292710)
60. Pecknold JC, Luthe L, Iny L, Ramdoyal D (1995). Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study. J Psychiatry Neurosci 20:193-198.
61. Pelland ME, Marchand A, Lessard MJ, Belleville G, Chauny JM, Vadeboncoeur A, et al. (2010). Efficacy of 2 interventions for panic disorder in patients presenting to the ED with chest pain. Am J Emerg Med 29:1051-1061.
62. Perna G, Bertani A, Caldirola D, Smeraldi E, Bellodi L (2001). A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 34:85-90. (Pubitemid 32531127)
63. Perna G, Alpini D, Caldirola D, Raponi G, Cesarani A, Bellodi L (2003). Serotonergic modulation of the balance system in panic disorder: an open study. Depress Anxiety 17:101-106. (Pubitemid 36407106)
64. Perna G, Favaron E, Di Bella D, Bussi R, Bellodi L (2005). Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology 30:2230-2235. (Pubitemid 41643974)
65. Pohl RB, Wolkow RM, Clary CM (1998). Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 155:1189-1195. (Pubitemid 28402511)
66. Pollack MH, Worthington JJ 3rd, Otto MW, Maki KM, Smoller JW, Manfro GG, et al. (1996). Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 32:667-670.
67. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R (1998). Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 55:1010-1016. (Pubitemid 28506843)
68. Pollack MH, Rapaport MH, Clary CM, Mardekian J, Wolkow R (2000). Sertraline treatment of panic disorder: response in patients at risk for poor outcome. J Clin Psychiatry 61:922-927. (Pubitemid 32058007)
69. Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, et al. (2003a). WCA recommendations for the long-term treatment of panic disorder. CNS Spectr 8:17-30. (Pubitemid 38419778)
70. Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, Toshkov F, et al. (2003b). Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 17:276-282. (Pubitemid 37150836)
71. Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y (2007a). A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl) 194:233-242. (Pubitemid 47457944)
72. Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, et al. (2007b). A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 24:1-14. (Pubitemid 46278675)
73. Pols HJ, Hauzer RC, Meijer JA, Verburg K, Griez EJ (1996). Fluvoxamine attenuates panic induced by 35% CO2 challenge. J Clin Psychiatry 57: 539-542. (Pubitemid 26412507)
74. Rampello L, Alvano A, Raffaele R, Malaguarnera M, Vecchio I (2006). New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. J Clin Psychopharmacol 26:67-70. (Pubitemid 43168391)
75. Reger MA, Welsh RK, Watson GS, Cholerton B, Baker LD, Craft S (2004). The relationship between neuropsychological functioning and driving ability in dementia: a meta-analysis. Neuropsychology 18:85-93. (Pubitemid 38167177)
76. Ribeiro L, Busnello JV, Kauer-Sant'Anna M, Madruga M, Quevedo J, Busnello EA, et al. (2001). Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 34:1303-1307. (Pubitemid 33014498)
77. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Panic Disorder and Agoraphobia (2003). Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust NZ J Psychiatry 37:641-656.
78. Sarchiapone M, Amore M, De Risio S, Carli V, Faia V, Poterzio F, et al. (2003). Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol 18:35-38. (Pubitemid 36127059)
79. Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995). Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408-412.
80. Seedat S, van Rheede van Oudtshoorn E, Muller JE, Mohr N, Stein DJ (2003). Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol 18:279-284. (Pubitemid 37041412)
81. Serretti A, Mandelli L (2010). Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 71:1259-1272.
82. Sharp DM, Power KG, Simpson RJ (1996). Fluvoxamine, placebo, and cognitive behavioural therapy used alone and in combination in the treatment of panic disorder and agoraphobia. J Anxiety Disord 10:219-242. (Pubitemid 26245113)
83. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, et al. (1997). Multicenter collaborative panic disorder severity scale. Am J Psychiatry 154:1571-1575. (Pubitemid 27471351)
84. Shieh G (2012). Confidence intervals and sample size calculations for the weighted eta-squared effect sizes in one-way heteroscedastic ANOVA. Behav Res Methods.
85. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J (1997). Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22:332-340. (Pubitemid 28035937)
86. Sim HB, Kang EH, Yu BH (2010). Changes in cerebral cortex and limbic brain functions after short-term paroxetine treatment in panic disorder: an [F]FDGPET Pilot Study. Psychiatry Invest 7:215-219.
87. Stahl SM, Gergel I, Li D (2003). Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64:1322-1327. (Pubitemid 37490237)
88. Van Balkom AJ, Bakker A, Spinhoven P, Blaauw BM, Smeenk S, Ruesink B (1997). A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis 185:510-516. (Pubitemid 27376660)
89. Van Vliet IM, den Boer JA, Westenberg HG, Slaap BR (1996). A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. J Clin Psychopharmacol 16:299-306. (Pubitemid 26254881)
90. Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, et al. (2002). Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 63:31-37. (Pubitemid 34113484)
91. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T (1997). The effect of citalopram in panic disorder. Br J Psychiatry 170:549-553. (Pubitemid 27418096)
92. Wagner W, Zaborny BA, Gray TE (1994). Fluvoxamine. A review of its safety profile in world-wide studies. Int Clin Psychopharmacol 9:223-227. (Pubitemid 24374883)
93. WagnerW, Hauser V, Wong LF (1996). The safety profile of fluvoxamine in elderly patients. Hum Psychopharmacol 11:267-272. (Pubitemid 26258866)
94. Wells GA, Shea B, O'Connell D (2005). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Available at: http://www. ohri. ca/programs/clinical-epidemiology/oxford. htm [Accessed 1 March 2012].
95. Zobel A, Maier W (2010). Pharmacogenetics of antidepressive treatment. Eur Arch Psychiatry Clin Neurosci 260:407-417.